News

FDA Warns Consumers, Health Care Professionals About Over-the-Counter Drug Products

Topics: Over the counter and Fda

FDA is advising consumers and health care professionals not to use Sit and Slim II, Dermatend Original, and Dermatend Ultra because the drug products are unapproved and could cause harm.

Read More →

NABP Issues Policy Statement Supporting the Pharmacist’s Role in Increasing Access to Opioid Overdose Reversal Drug

Topics: Patient safety and Prescription drug abuse

As the opioid overdose epidemic continues to take hundreds of lives each week, the National Association of Boards of Pharmacy® (NABP®) has issued a policy statement promoting an active role for pharmacists in expanding access to the opioid overdose reversal drug, naloxone. 

Read More →

NABP Seeks Nominations for 2015 Awards to be Presented at Annual Meeting

NABP invites you to nominate a colleague or board of pharmacy for a 2015 NABP award. 

Read More →

Pharmacy Robberies Plague Arizona, Other States, Says DEA

Topics: Diversion, Pharmacies, and Dea

Fueled by the prescription drug abuse epidemic, Arizona experienced the most pharmacy robberies in 2013 with 77 incidents, according to a report compiled by Drug Topics using Drug Enforcement Administration statistics. 

Read More →

FDA Orders New Jersey Company to Destroy Unapproved Drug Products

Topics: Fda

Federal authorities have ordered a New Jersey company to destroy its unapproved products and stop further manufacturing and distributing them until the drugs receive Food and Drug Administration (FDA) approval.

Read More →

NABP Issues Policy Statement Supporting the Pharmacist’s Role in Increasing Access to Opioid Overdose Reversal Drug

Topics: Pharmacists

As the opioid overdose epidemic continues to take hundreds of lives each week, the National Association of Boards of Pharmacy® (NABP®) has issued a policy statement promoting an active role for pharmacists in expanding access to the opioid overdose reversal drug, naloxone.

Read More →

FDA Announces Availability of Draft Guidance Regarding Licensure Standards Under Title II of the DQSA

Topics: Compounding and Fda

Food and Drug Administration (FDA) has issued a question-and-answer draft guidance document to assist industry and state governments in understanding the effects of section 585 (Uniform National Policy) of the Federal Food, Drug and Cosmetic Act added by Title II of the Drug Quality and Security Act (DQSA). 

Read More →

FDA Issues Draft Guidance on Pediatric Acetaminophen Products

Topics: Over the counter, Patient safety, and Fda

FDA has issued draft guidance with new recommendations for manufacturers of acetaminophen products.

Read More →

PTCB to Implement Changes in Continuing Education Requirements in 2015

Topics: Pharmacy technicians

The Pharmacy Technician Certification Board (PTCB) will implement two changes in recertification requirements for Certified Pharmacy Technicians (CPhTs) in accordance with its Certification Program changes announced in 2013. 

Read More →

FDA Provides Consumer Information on the Effect of OTC Medications on Driving

Topics: Patient safety and Fda

DA is reminding consumers that some over-the-counter (OTC) medications can affect the ability to drive and operate machinery safely in a new Consumer Update.

Read More →

Hospira Initiates Recall of Vancomycin Hydrochloride Due to Uncontrolled Storage During Transit

Topics: Compounding

Hospira, Inc, of Lake Forest, IL, has announced a voluntary global recall of one lot of Vancomycin Hydrochloride for Injection, USP, Equivalent to 1 g Vancomycin (Sterile Powder).

Read More →